Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMOR: Aflibercept Maintenance in Metastatic Colorectal Cancer
NCT01955629Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Dec 2013
- Primary completion
- Mar 2015
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aflibercept in colorectal cancer (metastatic) (mCRC), sponsored by Sanofi. Primary endpoints: Dose Limiting Toxicities and Progression Free Survival Rate at 6 Months. Started Dec 2013; status: terminated.
02
Drugs
aflibercept
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT01955629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01955629.